BCM
VRTX icon

Bridgeway Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bridgeway Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,300
Closed -$605K – 1301
2024
Q3 		$605K Hold
1,300
– – 0.01% 817
2024
Q2 		$609K Sell
1,300
-6,100
-82% -$2.65M 0.01% 820
2024
Q1 		$3.09M Sell
7,400
-5,900
-44% -$2.49M 0.06% 433
2023
Q4 		$5.41M Sell
13,300
-8,000
-38% -$2.96M 0.12% 282
2023
Q3 		$7.41M Sell
21,300
-7,050
-25% -$2.47M 0.18% 174
2023
Q2 		$9.98M Hold
28,350
– – 0.24% 116
2023
Q1 		$8.93M Buy
28,350
+2,700
+11% +$810K 0.24% 108
2022
Q4 		$7.41M Hold
25,650
– – 0.19% 165
2022
Q3 		$7.43M Buy
+25,650
New +$7.38M 0.2% 145
2021
Q1 		– Sell
-16,610
Closed -$3.93M – 1417
2020
Q4 		$3.93M Hold
16,610
– – 0.08% 301
2020
Q3 		$4.52M Buy
16,610
+2,660
+19% +$734K 0.1% 216
2020
Q2 		$4.05M Buy
13,950
+3,480
+33% +$943K 0.08% 235
2020
Q1 		$2.49M Buy
+10,470
New +$2.4M 0.06% 275
2019
Q2 		– Sell
-7,000
Closed -$1.29M – 1395
2019
Q1 		$1.29M Sell
7,000
-13,200
-65% -$2.44M 0.02% 668
2018
Q4 		$3.35M Sell
20,200
-29,100
-59% -$5.04M 0.04% 297
2018
Q3 		$9.5M Hold
49,300
– – 0.09% 182
2018
Q2 		$8.38M Hold
49,300
– – 0.09% 195
2018
Q1 		$8.04M Hold
49,300
– – 0.09% 182
2017
Q4 		$7.39M Hold
49,300
– – 0.08% 209
2017
Q3 		$7.5M Buy
49,300
+7,800
+19% +$1.17M 0.09% 200
2017
Q2 		$5.35M Buy
+41,500
New +$5M 0.06% 237

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bridgeway Capital Management's VRTX Position: Q4 2024 in Review

Bridgeway Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 1,300 shares — an estimated $605K sold.

Bridgeway Capital Management first reported a position in VRTX in Q2 2017 and held it in 21 quarters. The position peaked at $9.98M in Q2 2023. 1,564 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Bridgeway Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,300 Vertex Pharmaceuticals shares in Q4 2024, an estimated $605K.
  • Bridgeway Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 21 quarters.
  • Bridgeway Capital Management's Vertex Pharmaceuticals position peaked at $9.98M in Q2 2023.
  • 1,564 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Bridgeway Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.